Literature DB >> 1335592

Comparison of doxycycline and a chemically modified tetracycline inhibition of leukocyte functions.

W L Gabler1, J Smith, N Tsukuda.   

Abstract

Tetracyclines (Tc's) have the ability to inhibit neutrophil (PMN) functions which may be of value in the treatment of neutrophil-driven pathologic processes. However, long term use of Tc's frequently lead to emergence of antibiotic resistant strains of bacteria. A chemically modified analogue of Tc, 4DTc, having minimal antibiotic activity was compared to Dc, a member of the Tc family, for its ability to inhibit neutrophil functions. 4DTc was significantly less effective at inhibiting PMN superoxide synthesis, PMA-induced degranulation and PMN-mediated RBC lysis than was Dc. 4DTc and Dc were equally as effective inhibiting monocyte, but not PMN, adherence to gelatin-coated surfaces. When incubated in media containing varying 4DTc or Dc concentrations, Dc accumulated in RBC's and PMN's at levels 3 times greater than that found for similar media levels of 4DTc. The data suggest that the lesser ability of 4DTc to inhibit several PMN functions as compared to Dc may be related to its reduced intracellular accumulation. It also suggest that Tc inhibition of monocyte adherence may be more influenced by extracellular than intracellular processes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335592

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  9 in total

Review 1.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia.

Authors:  J Yrjänheikki; R Keinänen; M Pellikka; T Hökfelt; J Koistinaho
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Authors:  Y Du; Z Ma; S Lin; R C Dodel; F Gao; K R Bales; L C Triarhou; E Chernet; K W Perry; D L Nelson; S Luecke; L A Phebus; F P Bymaster; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

4.  Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat.

Authors:  W M Clark; N Lessov; J D Lauten; K Hazel
Journal:  J Mol Neurosci       Date:  1997-10       Impact factor: 3.444

5.  Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion.

Authors:  L Shapira; W A Soskolne; Y Houri; V Barak; A Halabi; A Stabholz
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

6.  Doxycycline reduction of F-actin content of human neutrophils and fibroblasts.

Authors:  W L Gabler; J Smith; N Tsukuda
Journal:  Inflammation       Date:  1994-02       Impact factor: 4.092

7.  In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis.

Authors:  A Lauhio; T Salo; Y Ding; Y T Konttinen; D Nordström; H Tschesche; J Lähdevirta; L M Golub; T Sorsa
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

Review 8.  Can tetracyclines ensure help in multiple sclerosis immunotherapy?

Authors:  Pedro Víctor-Carvalho; Rodolfo Thome; Catarina Rapôso
Journal:  J Clin Transl Res       Date:  2021-02-03

9.  What is the true in vitro potency of oxytetracycline for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida?

Authors:  L Dorey; S Hobson; P Lees
Journal:  J Vet Pharmacol Ther       Date:  2017-01-18       Impact factor: 1.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.